Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers August 27, 2016
Pharmacy Choice - News - U.S. Pharmaceutical Industry - August 27, 2016

Pharmacy News

 U.S. Pharmaceutical Industry
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

8/27/16 - Biotie: BTT1023 receives Orphan Drug Designation in the United States [Seven Days (United Arab Emirates)]
-BIOTIE THERAPIES CORP. STOCK EXCHANGE RELEASE 26 August 2016 at 2.30 p.m.. The United States Food and Drug Administration has granted Orphan Drug Designation in the United States for Biotie`s BTT1023 drug candidate for the treatment of primary sclerosing cholangitis. The BUTEO study is conducted in partnership with the University of Birmingham, UK
8/27/16 - Drugmaker pushed opioid cancer drug on patients with neck pain: state lawsuit [Chicago Tribune]
Aug. 26 Illinois Attorney General Lisa Madigan has sued an Arizona drug company for allegedly pushing its powerful opioid painkiller, Subsys, beyond its intended use on cancer patients. The lawsuit claims Insys directed its sales and marketing efforts in Illinois to "high-volume opioid prescribers" who are not oncologists, including one Chicago d
8/27/16 - EDITORIAL: Beware the company you keep: EpiPens and pharma bro Martin Shkreli [Chicago Tribune]
Aug. 26 In 2015, the so-called pharma bro Martin Shkreli vaulted to the top of America's Most Despised list. By crowing about how his company hiked the price of a vital drug by more than 5,000 percent. Cue the lightning bolts congressional inquiries, media scrutiny and a pitchfork brigade of customers who demanded a rollback of the price hike.
8/27/16 - Indian pharma steps up efforts on US safety standards [National, The (United Arab Emirates)]
Every third pill in the US is manufactured in India and India is the second largest supplier of medicine to the US, after Canada, he said. "For all of us in India, the US is very important," said Habil Khorakiwala, the founder chairman of Wockhardt, one of India's biggest pharma firms. "Irrespective of what are the FDA requirements, we need to cr
8/27/16 - Is Botox as safe as we think it is?
But a recent study from the University of Wisconsin-Madison has raised fresh doubts about how Botox works in the body. Botox first got FDA approval to treat medical ailments such as muscle spasms, excessive underarm sweating and eyelid tics. In 2002, the FDA approved the drug to be used cosmetically to minimize facial wrinkles, primarily the vertic
8/27/16 - NuvOx Pharma Awarded NIH Grant to Develop Technology to Treat Endocarditis
NuvOx Pharma, a Tucson based biotechnology company, has been awarded a grant from the Eunice Kennedy Shriver National Institute of Child Health and Human Development of the National Institutes of Health for $243,164.00 entitled, "Fibrin Targeted Microbubbles and Ultrasound for Treatment of Endocarditis." Shelby Kutty, MD, MS, PhD, Associate Profe
8/27/16 - OPINION: Maxwell: Truth? Lie? Time for the Malarkey Meter [Orlando Sentinel]
Ads get rated Minor Malarky, Major Malarkey, Maximum Malarkey or Totally True. The claim: Orlando mother Blanquita Trabold says her daughter was dying of cancer and needed a drug that didn't yet have FDA approval. But can members of Congress really help citizens get access to prescriptions?
8/27/16 - TG Therapeutics Announces Orphan Drug Designation for TG-1101 for the Treatment of Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorder [Arab News (Saudi Arabia)]
-TG Therapeutics, Inc. today announced that theU.S. As demonstrated with the announcement earlier this week of the orphan drug designation for TGR-1202 in the treatment of CLL, we are committed to building strong proprietary protection around our key compounds, which includes a multi-level patent strategy and orphan drug designations where appropri
8/26/16 - Akorn Relaunches Ofloxacin Otic Solution
Release date- 25082016- LAKE FOREST, Ill- Akorn, Inc., a leading specialty pharmaceutical company, today announced that it has relaunched Ofloxacin Otic Solution 0.3%, a sterile aqueous anti-infective solution for otic use. According to IMS Health, sales of Ofloxacin Otic Solution were approximately $33 million for the twelve months ended June 30,
8/26/16 - Akorn Relaunches Ofloxacin Otic Solution [Arab News (Saudi Arabia)]
-Akorn, Inc., a leading specialty pharmaceutical company, today announced that it has relaunched Ofloxacin Otic Solution 0.3%, a sterile aqueous anti-infective solution for otic use. According to IMS Health, sales of Ofloxacin Otic Solution were approximately $33 million for the twelve months ended June 30, 2016. Akorn has manufacturing facilities
8/26/16 - Akorn to Present at Morgan Stanley Global Healthcare Conference
Release date- 25082016- LAKE FOREST, Ill- Akorn, Inc., a leading specialty generic pharmaceutical company, today announced that Akorn's CEO, Raj Rai, will participate in a fireside chat at the Morgan Stanley Global Healthcare Conference. Akorn, Inc. is a specialty generic pharmaceutical company engaged in the development, manufacture and marketing
8/26/16 - Alcon Research Assigned Patent
ALEXANDRIA, Va., Aug. 26 Alcon Research, Fort Worth, Texas, has been assigned a patent developed by Bhagwati P. Kabra, Euless, Texas, for "aqueous pharmaceutical compositions containing borate-polyol complexes." The patent application was filed on April 20, 2015. Written by Kusum Sangma; edited by Jaya Anand.
8/26/16 - Amphetamines and other drugs in Baltimore's Gwynns Falls
Baltimore's streams have a drug problem. Researchers who sampled the Gwynns Falls on the western side of the city found a mix of pharmaceuticals and illicit drugs in the water, including a byproduct of heroin use. On two occasions a year apart, scientists sampled four streams in the Gwynns Falls watershed, from the city's suburbs to a point just up
8/26/16 - argenx Reports Second Quarter Business Update and Half Year 2016 Financial Results
*Successful Phase 1 multiple ascending dose study of ARGX-113 in healthy volunteers* Phase 2 study in first auto-immune indication planned to start by year-end* Cash position strengthened by $40 M upfront payment from AbbVie and ?30 M private placement Management to host conference call today at 3 pm CET/ 9 am EDT 26 August 2016 Breda, the Nether
8/26/16 - Biotie: BTT1023 receives Orphan Drug Designation in the United States
STOCK EXCHANGE RELEASE 26 August 2016 at 2.30 p.m. Biotie: BTT1023 receives Orphan Drug Designation in the United States The United States Food and Drug Administration has granted Orphan Drug Designation in the United States for Biotie's BTT1023 drug candidate for the treatment of primary sclerosing cholangitis. The BUTEO study is conducted in...
8/26/16 - Block & Leviton LLP Announces The Filing Of A Class Action Lawsuit Against Keryx Biopharmaceuticals Inc. For Violations Of The Federal Securities...
Block& Leviton LLP Announces The Filing Of A Class Action Lawsuit Against Keryx Biopharmaceuticals Inc. For Violations Of The Federal Securities Laws. By a News Reporter-Staff News Editor at Drug Week Block& Leviton LLP, a securities litigation firm representing investors nationwide, announces that Keryx Biopharmaceuticals Inc. and certain of its
8/26/16 - Can-Fite Reports Financial Results for Six Months Ended June 30, 2016
PETACH TIKVA, Israel, Aug. 26, 2016/ PRNewswire/ Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs being developed to treat inflammatory diseases, cancer and sexual dysfunction, today reported financial results for the six months ended June 30, 2016 and updates on its drug development programs.
8/26/16 - Clinton swipe sees flight from drug stocks
The FTSE 100 index was down 18.88 points to 6816.9 after Mrs Clinton hit out at the 480 per cent price rise of an allergy product owned by US pharma firm Mylan. The comments from across the Atlantic caused investors to take flight from London- listed drug stocks, with Hikma Pharmaceuticals and Shire dropping 78 p to 2150 p and 123 p to 4902 p respe
8/26/16 - Company Profile for Trevena, Inc.
By a News Reporter-Staff News Editor at Drug Week Trevena, Inc. is a clinical stage biopharmaceutical company focused on discovering and developing biased ligands to deliver the next generation of GPCR targeted medicines. Trevena's oliceridine is in Phase 3 development for the management of moderate to severe acute pain, and is the first pain pro
8/26/16 - EDITORIAL: Beware the company you keep: EpiPens and pharma bro Martin Shkreli [Chicago Tribune]
Aug. 26 In 2015, the so-called pharma bro Martin Shkreli vaulted to the top of America's Most Despised list. By crowing about how his company hiked the price of a vital drug by more than 5,000 percent. Cue the lightning bolts congressional inquiries, media scrutiny and a pitchfork brigade of customers who demanded a rollback of the price hike.
8/26/16 - EDITORIAL: Drug companies must answer for price hikes [The Times-Tribune, Scranton, Pa.]
Aug. 26 Mylan Pharmaceuticals has responded to heavy pressure for its alleged price-gouging in a way that does not resolve the problem. Since 2009, the company has increased the price of the product from about $100 per two-dose pack to as much as $600. The Department of Justice and the Federal Trade Commission should investigate the price increas
8/26/16 - EDITORIAL: Life-saving drug? Investigate prices [The Santa Fe New Mexican]
This medicine comes out in potentially life-threatening situations, when an allergic reaction or bee sting is sending the body into anaphylactic shock. That's why it is particularly galling that the price of the pens is soaring for no apparent reason up from about $47 for a single pen in 2007 to $284 this summer. Oh, and a consumer can no longe
8/26/16 - EPIPEN ANGER GETS ACTION
The maker of EpiPens said Thursday that the company will offer a $300 discount for the lifesaving allergy shot in the wake of complaints from patients and politicians after the cost of a prescription increased to more than $600 this year. The move comes amid calls for a federal investigation and increasing ire in Congress about how the price increa
8/26/16 - EPIPEN MAKER TO OFFER COUPONS
The maker of EpiPens said Thursday that the company will offer a $300 discount for the lifesaving allergy shot in the wake of complaints from patients and politicians after the cost of a prescription increased to more than $600 this year. The move comes amid calls for a federal investigation and increasing ire in Congress about how the price increa
8/26/16 - First Product Approved for ME/CFS Indication Anywhere in the World Breakthrough Approval Provides Clear Path for Growth in Latin America and the European Union - Press Release issued by HemispherxBiopharma [Pakistan Press International]
HemispherxBiopharma, Inc., announced that it has received approval of its New Drug Application from AdministracionNacional de Medicamentos, Alimentos y TecnologiaMedica for commercial sale of rintatolimod in the Argentine Republic for the treatment of severe myalgic encephalomyelitis/chronic fatigue syndrome. The product will be marketed by GP...
Articles(s): 1 - 25 of 250     Next >>     Go To Page:


© 2016 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
RxSchool
Pharmacy Spanish
This lesson is supported by:
RxSchool
Drug Therapy Management Series Part III: Geriatric Disorders
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2009 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415